Index Intelligence

441 digests in this category

· daily

S&P 500 Technology Sector SEC Filings — May 14, 2026

Across 41 filings in the USA S&P 500 Technology stream, a dominant theme is robust revenue acceleration in select tech, space, and comms firms (e.g., Applied Materials +11% YoY to $7.91B, Intuitive Machines 3x YoY to $186.7M, GameSquare +95% YoY to $14.5M), contrasted by profitability volatility and cash burn pressures amid M&A (Iridium $366.7M Aireon deal, Intuitive $800M Lanteris). Period-over-period trends show 7/15 quarterly reporters posting YoY revenue growth averaging +55% (outliers: ImmuCell +28%, RideNow +6.4%), but 6/15 saw net losses widen or emerge (avg -45% net income swing), with margins mixed (Applied +80bps to 49.9%, ImmuCell +340bps to 45%). Institutional 13F snapshots reveal concentrated tech bets (Broadcom $250M Paradigm, Analog Devices $216M Timucuan, TSMC/Amazon ~$20M H Squared), signaling conviction in semis/AI/cloud. Forward-looking catalysts cluster in Q3 2026 (Applied rev ~$8.95B, Iridium deal close), while capital allocation leans shareholder-friendly (Applied div +15% to $0.53). Biotech-adjacent tech like INmune Bio's FDA Fast Track adds upside, but BDC/niche declines (Muzinich income -38% YoY) flag sector divergence. Overall, actionable alpha in growth outperformers pre-earnings/M&A closes, with risks in cash-strapped turnarounds.

13 high priority 28 medium 41 total filings
· daily

Nasdaq 100 Stocks SEC Filings — May 14, 2026

The 48 filings from NASDAQ-100 constituents and related entities reveal mixed Q1 2026 results across 15 earnings reporters, with 8/15 showing YoY revenue growth averaging +28% (e.g., ImmuCell +28%, INBS +46%, Intuitive Machines +200%), but persistent net losses in 12/15 amid rising G&A/exploration costs; margin expansions noted in 4/15 (e.g., INBS +370 bps gross margin). Key themes include accretive M&A (Iridium-Aireon adding $100M rev, Intuitive Machines-Lanteris boosting backlog to $1.1B), regulatory wins (TMC NOAA compliance by Q1 2027, INmune Bio FDA Fast Track), and institutional positioning via 13Fs favoring mining/tech (e.g., Mudita heavy in gold/mining, Paradigm in semis). Capital allocation leans conservative with dividend hikes (Applied Materials +15% to $0.53/share) but no buybacks noted; cash burns improved in 6/15 ops cash flow metrics. Portfolio-level trends show metals/biotech outperformance in milestones vs. services revenue softness (Intellinetics -8%). Forward catalysts cluster in H2 2026 (deal closes, trial data), signaling alpha in space/mining amid AI/semicon strength. Overall, bullish on strategic progress offsetting losses, with watch for cash runway in microcaps.

19 high priority 29 medium 48 total filings
· daily

S&P 500 Financials Sector SEC Filings — May 14, 2026

Across 50 filings from the USA S&P 500 Financials stream (including banks, insurers, asset managers, and related SPACs/BDCs), dominant themes include SPAC quarterly resilience via trust interest income (10 SPACs averaging +$1.4M net income Q1 2026 despite ops losses and cash burns QoQ 20-67%), active debt markets with refinancings/upsizes (Lumen $2.4B Term B-5, Encore €325M notes), and mixed operating results in financial-adjacent firms (revenue growth in 8/15 ops cos avg +45% YoY skewed by small caps like Lifeway +37%, Karman +51%, but declines in larger like New Fortress -52%, Apartment REIT -4.8%). Period-over-period trends reveal margin expansions in outliers (Lifeway +360bps, Intelligent Bio +380bps to 50.5%) contrasting compressions elsewhere (SpringBig gross -16.8%), with capital allocation favoring debt raises over buybacks/dividends (News Corp $1B program ongoing, Muzinich no distributions). Forward-looking signals positive for growth (Lifeway FY2027 EBITDA $45-50M, Health In Tech scaling in $1T market), but SPAC risks high (Cantor 22M shares redeemed -$234M trust, Vernal going concern). Portfolio-level: Neutral 13Fs (Lord Abbett $30M, Gemsstock $949M energy tilt), bullish catalysts in M&A (Presidio $83M oil/gas), bearish cash burns signal caution; actionable now: Favor debt-access firms, monitor SPAC combos.

32 high priority 18 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — May 14, 2026

Across 50 filings primarily from small-cap biotechs, medtech, financials, and institutional 13F-HR snapshots (despite Consumer Staples stream focus, data skews pharma/services), Q1 2026 results show mixed performance: 8/15 quarterly reporters achieved revenue growth averaging +28% YoY (e.g., Intelligent Bio +46%, NIQ +11.1%), but 12/15 widened net losses (avg +45% YoY) amid rising opex/R&D, with cash burn improving in 6 cases. Key themes include M&A completion (Apellis acquired by Biogen at $41/share + CVR), positive clinical data (Cellectar 61.8% MRR), financing successes ($140M for Cellectar, $50M loan for Pelthos), and neutral 13F holdings in tech/ETFs signaling steady institutional conviction. Capital allocation leans defensive (dividends at Chicago BDC $0.34/share, reverse splits at Reliance), with forward guidance reaffirmed (NIQ 5-5.3% OCC growth). Portfolio-level trends: margin expansion in 4/10 (Intelligent Bio +380bps), but compression elsewhere; biotech outliers shine on milestones vs deteriorating liquidity in 7 firms (cash down >50% QoQ). Implications: tactical opportunities in catalysts (ASCO June 1), but watch liquidity risks and delistings amid volatile small-caps.

15 high priority 35 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — May 14, 2026

Across the 50 filings in the USA S&P 500 Industrials stream, sentiment skews mixed-positive, driven by robust revenue growth in select industrials and energy-adjacent names like Forgent Power Solutions (+103% YoY to $379M revenue, +308% bookings) and LanzaTech (+26% YoY revenue), contrasting with persistent net losses in biotechs despite R&D progress. Period-over-period trends reveal 8/18 quarterly reporters with YoY revenue growth averaging 52% (outliers: Forgent 103%, Intelligent Bio 46%), but 10/18 showed net loss widening (avg +35% YoY) due to OpEx ramps; margins expanded in 5 cases (e.g., Forgent Adj EBITDA +96% to 22.4%). Institutional 13Fs (17 filings) highlight concentrated ETF exposure and defense industrials like Lockheed Martin ($10.5M in Campion), signaling broad sector conviction. Capital allocation shines with CSX's $5B buyback authorization atop $989M remaining, while M&A (Apellis acquired at $41/share + CVR) and debt raises (Constellation $2.2B notes) bolster liquidity. Forward-looking data flags raised guidances (Forgent FY26 rev +82% YoY midpoint, Hyperion +20%) and catalysts like Cabaletta's mid-2026 data readouts. Portfolio implications: Tactical buys in high-growth industrials amid biotech volatility, monitor June 2026 debt events.

19 high priority 31 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — May 14, 2026

The S&P 500 Energy sector filings reveal strong shareholder confidence in governance at majors ConocoPhillips and Phillips 66, with near-unanimous approvals for directors, auditors, and exec comp amid rejected independent chair proposal at COP. A wave of 13F-HR disclosures from institutions like Blue Whale Capital ($2.1B portfolio, NVIDIA/Lam top), Fuller & Thaler ($29.7B, industrials focus), and Noked Israel ($677M, semis heavy) shows minimal evident energy exposure in top holdings, suggesting investor sidelining of oil/gas amid tech preference. Apartment Income REIT's Q1 10-Q flags mixed results: revenues -4.8% YoY to $193.7M, net loss $(28.9M) vs prior profit, but operating cash +376% YoY to $39.6M and interest expense -13.5% to $81.2M. No insider trades, M&A, or guidance changes noted across filings; capital allocation subdued with REIT capex -48% YoY to $12.8M. Portfolio-level trend: neutral institutional positioning, positive energy AGM outcomes contrast REIT weakness, implying stable but uninspiring sector momentum into Q2 2026.

2 high priority 10 medium 12 total filings
· daily

Dow Jones 30 Stocks SEC Filings — May 14, 2026

Across 50 SEC filings from May 14, 2026, primarily Q1 2026 10-Qs and 8-Ks, a key theme is robust revenue growth in 12/20 reporting companies averaging 67% YoY (e.g., RenovoRx +186%, Barfresh +92%, Aveanna +15.9%), driven by commercial expansion and segment gains, though offset by widening losses in 8 cases due to rising SG&A/R&D (avg +25% YoY). Biotech and healthcare firms dominate with clinical catalysts (e.g., Corvus Phase 1 success, RenovoRx trial enrollment by June), while telecom (Verizon) and consumer (YETI) show stable financing/debt access. Margin trends mixed: expansions in Enovix (+495% gross profit), compressions in YETI (-210 bps) and Versant (-11% op income). Capital allocation favors repurchases/dividends (Versant $100M buyback, YETI $500M auth increase) amid cash raises ($30M LanzaTech, $150M Cabaletta). Forward guidance raised in 4 firms (Aveanna rev +$40M, YETI sales 7-8%), signaling confidence; DJ30 exposure limited but Verizon's $4B notes positive. Portfolio implication: selective buys in growth biotechs/healthcare with near-term catalysts, caution on expense-heavy small caps; alpha from M&A/turnarounds like Kennedy-Wilson merger.

21 high priority 29 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — May 14, 2026

Across 50 filings from May 14, 2026, primarily Q1 2026 results and 13F-HR holdings, the S&P 500 Consumer Discretionary stream reveals mixed performance with standout revenue accelerations in niche consumer-adjacent plays like Lifeway Foods (+37% YoY sales) and Newton Golf (operational expansions) amid broader sector challenges; however, energy-tied names like New Fortress Energy saw -52% YoY revenue collapses. Period-over-period trends highlight revenue growth in 7/15 operational filings averaging +85% YoY (outliers Forgent Power +103%, Scientist Home +321%), but margin pressures and capex surges led to net losses in 9/15 cases, with cash burns widening (e.g., WhiteFiber -33.8% QoQ cash). Institutional 13F-HRs (20+ filings) show heavy tech/consumer exposure (e.g., Nan Shan Life's $172M Alphabet, Swiss Life's massive Apple/Amazon), signaling conviction in discretionary leaders despite no direct insider buys noted. Forward-looking catalysts include raised guidances (Forgent FY2026 rev $1.35-1.39B, Hyperion DeFi gross profit $5-7M) and events like FREIT's Fall 2026 liquidation vote. Capital allocation leans toward capex/reinvestment (Lifeway $11M, Fermi $441M) over dividends/buybacks, with debt raises common (Wayfair $400M notes). Portfolio-level theme: Resilient growth pockets in food/golf/power contrast retail/energy weakness, favoring selective longs on guidance beats.

14 high priority 36 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — May 14, 2026

Across 50 filings in the USA S&P 500 Healthcare intelligence stream (despite cross-sector inclusions), Q1 2026 results from 10+ companies reveal robust revenue growth averaging +150% YoY in growth-oriented firms like Lifeway (+37%), Scientist Home (+321%), and UMeWorld (+85,000%), but persistent margin compression (-1,200bps avg in 5/8 cases) and opex explosions (+500% avg) drove wider net losses in 7/10, with cash burn accelerating and positions declining QoQ in 8/10 (e.g., Cellectar -37%, Senti -46%). Healthcare standouts include bullish biotech catalysts: Cellectar’s 61.8% major response rate in WM Phase 2b (iopofosine I 131), Editas’ 90% LDL-C reduction in NHP preclinical, and Senti Bio’s 70% YoY net loss reduction plus FDA pivotal trial nod. Institutional 13Fs (25/50 filings) signal conviction in healthcare via top holdings like McKesson (Seaview #1), AbbVie (multiple incl. Weaver, HRT, MFS), and biotechs Mineralys/Phathom (Catalys 93% portfolio). Capital allocation leans growth/reinvestment (Lifeway $11M capex, Cellectar $140M financing, Sixth Street $300M notes), with deal closes (HPE $987M) and backlogs (New Fortress $10B thru 2030) providing visibility. Portfolio implications: overweight biotech catalysts for alpha, underweight high-burn small caps amid liquidity risks; monitor ASCO June 1 and H1 2026 events.

11 high priority 39 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — May 13, 2026

Across the 7 filings in the USA S&P 500 Energy intelligence stream, only Devon Energy provides direct sector exposure via its $475M stake in Waterbridge Infrastructure, signaling conviction in energy infrastructure amid neutral institutional 13F snapshots from managers favoring tech and industrials. Period-over-period trends in 10-Q filers reveal volatility: KAANAPALI LAND exploded with +4,529% YoY revenue to $20.4k from property sales, Winchester Bancorp posted +44% YoY net interest income and +11.4% assets, while Hughes Satellite saw -11.2% revenue but narrowed losses dramatically. Mixed sentiments dominate (3/4 applicable), with no insider trading activity disclosed, limited capital allocation (e.g., KAANAPALI's $981 distribution), and no forward-looking guidance except Hughes' going concern warning. Portfolio-level patterns show institutions maintaining diversified, tech-heavy positions with no major shifts QoQ/YOY. Key implication: Sparse direct energy insights, but Devon's outsized Waterbridge holding flags infrastructure opportunity; monitor non-energy filers for broader market spillovers into energy via capital flows. Overall, bullish turnarounds in KAANAPALI/Winchester contrast Hughes' distress, urging selective positioning.

3 high priority 4 medium 7 total filings
· daily

S&P 500 Industrials Sector SEC Filings — May 12, 2026

The 50 filings for USA S&P 500 Industrials stream are dominated by 37 neutral 13F-HR disclosures from global managers (US, Hong Kong, Australia, Singapore), revealing Q1 2026 portfolios heavily concentrated in tech mega-caps (Apple, MSFT, NVDA topping 80% of filings, e.g., Circle Wealth 43% AAPL) and broad ETFs, signaling sustained institutional conviction in growth equities amid diversified risk via treasuries/quality factors. Operational filings (13 total) show mixed but resilient industrials trends: Ducommun (aerospace/defense) posted record Q1 revenue +9% YoY to $209M with gross margins +70bps to 26.9% and adj EBITDA +19%; Venture Global (LNG/infra) surged revenue +59% YoY to $4.6B, raising FY26 EBITDA guidance to $8.2-8.5B with new $8.6B project financing. Contrasts include sharp declines (VenHub revenue -86% YoY, Next Bridge -11% YoY with no reserves/employees) and ongoing losses (Verde Clean Fuels improved net loss to $2.4M YoY but cash burn persists; BCSF NII -8% QoQ, NAV -2.2%). Capital allocation leans supportive (BCSF $0.42 dividend covered, Venture $0.02/share, issuances for growth), with catalysts like S&P Global Mobility Investor Day (May 12, 2026) and leadership positives (Diodes new Chair). No insider transactions reported across filings; sector portfolio-level trends highlight aero/defense outperformance vs. energy explorers' weakness, positioning industrials for infra/LNG tailwinds but destocking risks.

7 high priority 43 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — May 12, 2026

The May 12, 2026, filings for S&P 500 Consumer Discretionary reveal heavy institutional conviction via 40+ 13F-HRs, with Amazon.com as a top holding across 12 portfolios (e.g., 17.9%/$134M at GCQ Funds, $999M at Mitsubishi UFJ, $306M at United Super), alongside Uber (14%/$105M at GCQ) and exposure to eBay peers, signaling sustained allocation to e-commerce and ride-sharing amid neutral sentiment. Operational highlights include Aramark's robust Q2 FY2026 results (+15% YoY revenue to $4.9B, +12% organic, +40% adj EPS to $0.49, +116% FCF), eBay's rejection of GameStop's non-binding $20B debt-financed bid citing $80B 2025 GMV standalone strength, and mixed hospitality metrics like Ashford Hospitality's hotel sale improving pro forma net loss -4% YoY and SmartStop Self Storage's occupancy dip -70bps YoY to 92.3%. Period trends show growth divergence: 15-115% YoY revenue surges in services/infra (Aramark, JFB Construction, Cardinal Infrastructure) vs declines in volumes/occupancy (-11% rev at Next Bridge, rates down at SmartStop). Forward guidance is optimistic (e.g., Figure's Q2 vol $3.8-4.1B, Cardinal FY rev raised to $675-685M, Aramark leverage <3x FYE), with capital returns via Aramark's $25M buyback/$55M debt paydown/$0.12 dividend and Sound Financial's dividend hike to $0.21/share. Executive risks emerge (HF Sinclair CEO separation $4.7M severance, CFO leave), but no broad insider selling; overall, bullish flows favor selective e-comm/services overweight with hospitality watch.

12 high priority 38 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — May 11, 2026

Across 50 filings in the USA S&P 500 Consumer Staples intelligence stream (though spanning broader sectors like energy, biotech, and finance), mixed sentiment prevails with 12/20 high-materiality operational filings showing revenue growth (avg +35% YoY where positive, e.g., CleanCore +113%, Kodiak +6.2%) offset by widespread net losses or margin compression (e.g., HAIN -13% sales, OPAL -14% rev). Period-over-period trends reveal portfolio-level margin deterioration averaging -100bps in 6/10 reporting firms amid rising G&A (e.g., CleanCore +1350% YoY) and impairments, but capital allocation shines with debt reductions (ARKO -50% total debt QoQ, HAIN -$155M), buybacks/tenders (FS KKR $450M program), and reaffirmed/raised guidance (Kodiak EBITDA to $820-860M). Biotech and energy outliers like MoonLake/Intellia (BLA catalysts H2 2026) and Constellation (+1247% NI YoY) signal resilience, while 25+ 13F-HRs indicate steady institutional conviction in tech/ETFs (e.g., Apple, NVIDIA top holdings). Key implications: Favor debt deleveragers and guidance raisers for near-term alpha; monitor liquidation risks (Elme) and crypto volatility (CleanCore -$107M digital loss). Overarching theme: Defensive staples under pressure, but M&A/capex in adjacents (Calpine acquisition) drives upside.

11 high priority 39 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — May 11, 2026

Across 50 filings in the S&P 500 Healthcare stream, 13F-HR reports dominate (over 60%), revealing institutional portfolios overwhelmingly tilted to tech megacaps (Apple, MSFT, NVDA topping 25+ filers, e.g., $709M Apple in Cincinnati Financial) with secondary but stable healthcare exposure (AbbVie $270B Citigroup, $305M Cincinnati Insurance, Lilly $7M CIGNA). Healthcare-specific filings highlight biotech momentum with positive clinical data (Inhibrx Phase 2 ORR 44% vs 21% control +24% edge, MBX Biosciences 7% weight loss Phase 1) contrasting small-cap deterioration (Elicio Q1 loss widened to $11.8M +5% YoY, BioScience rev -38.8% YoY to $0.75M). Adjacent financials show resilient NII growth averaging +12% YoY (Esquire +23%, C&F +11%, Flushing swing to $5.8M profit) amid rising provisions (+20-100%). Capital allocation leans shareholder-friendly (Ellington monthly $0.13 dividend June 30, News Corp $1B buyback ongoing, Flushing dividend doubled to $0.44), but dilution risks loom (ACRES ~105% share issuance vote). Forward catalysts cluster Q3-Q4 2026 (Inhibrx Phase 3/PFS, MBX 12-wk data); neutral-to-mixed sentiment prevails with no notable insider trading patterns. Portfolio implication: tactical biotech alpha amid broad market tech rotation, monitor dilution votes.

11 high priority 39 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — May 07, 2026

Across 50 SEC filings dated May 7, 2026, primarily Q1 FY2026 results for diverse firms (despite Consumer Staples labeling, spanning consumer brands, biotech, energy, finance), revenue trends are mixed with standout growth in branded consumer plays (Celsius +138% YoY to $782.6M, Kontoor Brands +45% to $613M continuing ops, Tapestry +21% to $1.92B) contrasting declines (Aspen Aerogels -52% to $37.9M, Krispy Kreme -2.2% to $367M, Rockwell Medical -8% to $17.3M). Margin expansions prevalent in 7/15 detailed reporters (ARKO fuel +20.1% to 48c/gal, Krispy Kreme EBITDA +380bps to 9%, Callaway gross +250-260bps), but compressions hit growth firms (Claritev EBITDA margin -140bps to 60%, Celsius gross -400bps to 48.3%). Guidance largely raised or steady (Kontoor FY rev $3.41-3.46B up, Callaway sales $2.015-2.07B raised $35-70M, Tapestry ~$7.95B +14%; ARKO unchanged $245-265M EBITDA), signaling management conviction amid YoY improvements in net losses (ARKO -56% narrower, Climb Bio -34%). Capital allocation aggressive with buybacks (Kontoor $750M new auth, GigaCloud $12.3M Q1/$68M remain, Callaway 5.6M shares), dividends (ARKO $0.03/sh, Dorian LPG irregular $1.00/sh), and debt reduction (ARKO $206M via IPO). Biotech pipeline catalysts dense (Climb Bio Fast Track/FDA orphan, Monte Rosa Phase 2 H2 2026), while cash flows deteriorated in 6/12 (GigaCloud op cash $(21.7)M vs +$9.4M YoY, Claritev FCF $(92.5)M worse). Portfolio-level: 14/22 Q1 reporters avg +28% rev growth but -15% avg op cash YoY; mixed sentiment (18/22 mixed) implies selective opportunities in margin outperformers and guidance raisers.

22 high priority 28 medium 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — May 07, 2026

Across the 50 SEC filings from Dow Jones 30-related streams, dominant themes include robust M&A and SPAC activity in nuclear/energy (Hennessy/ONE Nuclear, General Fusion, Catalyst Pharma acquisition), explosive revenue growth in consumer products (Celsius +138% YoY, Kontoor +45% YoY), and biotech pipeline advancements amid cash burns (Vera PDUFA July 2026, Evommune Phase 2b readouts). Period-over-period trends show 18/25 detailed filers with YoY revenue growth averaging +35% (range -4% to +167%), but margins mixed with 9 expansions (avg +200 bps, e.g., MasterCraft +420 bps) vs 7 compressions (avg -150 bps, e.g., Celsius -400 bps); EBITDA improvements in 14 cases (avg +50%). Critical developments: 5 M&A/mergers (e.g., Catalyst $4.1B at 21-28% premium, MasterCraft vote May 12), 4 guidance raises (Kontoor revenue to $3.41-3.46B, AvePoint ARR $523-529M), and equity/debt raises ($405M Avalo, $750M Booking notes). Portfolio-level patterns flag sector rotation opportunities in consumer/energy (+100%+ growth outliers) vs telecom/utilities caution (Optimum -4% rev, impairments), with capital returns via buybacks ($750M Kontoor, $24M Celsius) signaling conviction amid mixed sentiment (14/25 mixed, 6 positive). Implications: Bullish for acquisitive consumer/biotech names, monitor nuclear catalysts for DJ30 energy proxies.

29 high priority 21 medium 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — May 06, 2026

Across 39 filings in the S&P 500 Technology stream, institutional 13F-HR reports (e.g., Munro, Amica, Palladiem) reveal persistent heavy concentration in core tech names like NVIDIA (top holding in 4/10 13Fs, $288M-$61M positions), Apple, Microsoft, Amazon, and Meta, signaling sustained conviction amid AI/hardware boom. Operational tech firms showed divergent Q1 2026 trends: AMD revenue +38% YoY to $10.3B, EPS +91% to $0.84; Arista +35% to $2.7B, op income +35% to $1.16B; contrasting Ribbon's -10% revenue decline to $163M and widening net loss. Non-tech inclusions highlight cross-sector capital shifts, with positive turnarounds in shipping (Genco +61% rev) but weakness in BDCs (Palmer Square NAV -11% QoQ). Capital allocation mixed: Arista paused buybacks after $787M prior year, while Genco hiked dividend 133% YoY to $0.35/share; forward guidance stable/reaffirmed in Acadia/Immunocore. Portfolio-level: 7/12 10-Qs showed revenue growth averaging +22% YoY, but margin pressures in 4/12 (avg -50bps compression). Key implication: Tech growth intact but watch cash burn/expenses in smaller caps; institutional flows favor AI leaders.

16 high priority 23 medium 39 total filings
· daily

Nasdaq 100 Stocks SEC Filings — May 06, 2026

Across 35 filings from NASDAQ-100 related entities, Q1 2026 earnings reveal robust revenue growth in 8/12 operating companies (avg +18% YoY, led by AMD +38% and Kennametal +22%), but mixed profitability with 6/12 showing margin compression or expense pressures (avg op margin flat to -100bps). Institutional 13F-HR filings (13/35) highlight concentrated tech exposure, with NVIDIA topping 5 funds (e.g., Munro $288M, AMICA $61M), signaling sustained conviction in AI/semiconductors. Shipping (Genco) posted a sharp turnaround (+60% revenues, dividend +133% YoY), while biotechs (Immunocore +14% sales, Lyell loss -54%) and autos (Adient +7% sales, profit swing) show recovery glimmers amid cash burn concerns. Capital allocation leans shareholder-friendly with dividends declared in 5 firms (e.g., Genco $0.35, Kennametal $0.20) and buybacks (United Community $37M, Mueller $5.5M). Forward guidance mostly raised/affirmed (Kennametal EPS +18%, Murphy prod beat), building a catalyst-rich H2 2026 calendar. Portfolio implication: Overweight growth industrials/tech, monitor inventory drags and biotech trials for alpha.

14 high priority 21 medium 35 total filings
· daily

S&P 500 Financials Sector SEC Filings — May 06, 2026

Across 50 SEC filings from S&P 500 Financials and related streams dated May 6, 2026, key themes include mixed Q1 2026 earnings with 14/22 reporting companies showing YoY revenue growth averaging +15% (e.g., Clear Secure +19.7%, Amcor +77%), but margin compression in 10/22 averaging -180 bps amid higher costs and investments; robust capital allocation via dividends/buybacks in 9 filings (e.g., Acushnet $10M repurchase, Clear $56.4M returns); and active M&A/debt markets with SPAC IPOs (Quantum Leap $200M, Plutonian $100M) and financings (Bread Financial 4.8M pref shares, Blackstone $450M notes). Financials-specific trends highlight mortgage/REIT consolidation (Two Harbors $11.30/share acquisition at 14% premium) and bank procedural updates (Woori dissent notices, Patriot Q1 prelims). Forward-looking signals positive with 8/15 guidance raises (e.g., BeOne revenue to $6.3-6.5B, LivaNova EPS to $4.20-4.30), building a Q2-Q3 catalyst calendar; 13F-HR filings (14 total) reveal concentrated tech/AI bets (NVIDIA top in 5/14). Portfolio implications: overweight resilient growth names with raised guidance, monitor margin pressures and SPAC de-SPAC risks for alpha.

18 high priority 32 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — May 06, 2026

Across 50 pre-analyzed SEC filings in the USA S&P 500 Consumer Staples intelligence stream (despite diverse sector representation), Q1 2026 results reveal resilient revenue growth in 70% of reporting companies (avg +9% YoY, ranging from PureCycle +161% to QuidelOrtho -10.5%), tempered by mixed margins (expansions in Elanco +21% Adj EBITDA, Clear Secure +720 bps; compressions in Edgewell -410 bps, Kraft Heinz adj op inc -11.8%). Capital allocation trends emphasize shareholder returns with 15+ companies declaring dividends (e.g., Deluxe $0.30/share, Clear Secure $0.15/share + $56M repurchases) and buybacks (TKO +$1B authorization), alongside debt reductions (Deluxe -$32M, Littelfuse -$166M). Forward-looking statements show 60% guidance raises/reaffirms (Elanco revenue $5.01-5.085B +5-7% org CC, Clear Secure FCF +35.5%), building a catalyst calendar amid M&A momentum (Apellis $41/share + CVR tender, Clear Channel $2.43/share merger by Q3'26). Sentiment skews mixed (55%), with positive outliers in consumer-facing growth (Clover Health rev +62%, members +51%) but bearish pressures from impairments/litigation (Atkore $137M settlement, Fresh Del Monte $20M). Portfolio-level patterns indicate sector stability via promotions (GIS COO elevation) and operational turnarounds (JBT Marel net income +$218M YoY), signaling actionable opportunities in undervalued staples amid modest organic growth (Kraft Heinz -0.4%, Edgewell -2.4%). Overall implications favor defensive positioning with selective growth bets on guidance outperformers.

20 high priority 30 medium 50 total filings